-
Posted by
Two Blokes Mon at 11:30 AM -
Filed in
Stock
-
1 view
Despite Novo Nordisk's stock decline, the company's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. Eli Lilly's oral weight-loss drug announcement caused undue panic; NVO's advanced pipeline, including oral semaglutide and Amycretin, remains highly competitive. The partnership with Hims & Hers mitigates legal risks and boosts distribution, promising significant synergies and long-term benefits for the Company.
